- Home
- DQ vs EYPT Comparison
DQ vs EYPT Comparison
Compare DQ & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DQ | EYPT |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2010 | 2005 |
Fundamental Metrics
Financial Performance| Metric | DQ | EYPT |
|---|---|---|
| Price | $18.51 | $13.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $28.91 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 858.0K | 792.6K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $69.82 | N/A |
| Revenue Next Year | $34.34 | $3,115.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.83 | $5.46 |
| 52 Week High | $36.59 | $19.11 |
Technical Indicators
Market Signals| Indicator | DQ | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 37.68 | 48.30 |
| Support Level | $17.89 | $13.61 |
| Resistance Level | $23.84 | $14.74 |
| Average True Range (ATR) | 1.13 | 0.76 |
| MACD | -0.19 | 0.02 |
| Stochastic Oscillator | 12.44 | 52.09 |
Price Performance
Historical ComparisonAbout DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.